Upload

Loading...

Enterprise Ireland 'Big idea' Awards - Lifesciences & Food Commercialisation Award Winners

452 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Uploaded on Nov 9, 2011

Winner of the Enterprise Ireland Lifescience & Food Commercialisation Award:
Clinical Support Information Systems Ltd (CSIS) - winner of The Enterprise Ireland Lifescience & Food Commercialisation Award 2011
Clinical Support Information Systems Ltd (CSIS) is a company built around the STOPP-START technology developed at University College Cork by an inter-disciplinary group of clinicians, pharmacists and computer scientists. Gerry Moran, the CEO of CSIS, is working in partnership with the researchers, the UCC Technology Transfer Office and Enterprise Ireland to bring the STOPP-START to market.
The research team behind the technology which was developed with commercialisation funding from Enterprise Ireland are: Denis O'Mahony, Stephen Byrne, Sean Og Murphy, Cristin Ryan, Ken Brown and Cormac Sreenan.
STOPP/START is designed specifically with the older patient in mind and the particular medication problems encountered in this age group (older people consume about half of all prescription medicines in Ireland and Europe).
STOPP/START lists the common instances of potentially inappropriate medicines (STOPP list) and potential prescribing omissions (START list); the presence of STOPP medicines and the absence of START medicines may be highly detrimental to the older patient, in particular the frailer person with multiple chronic disorders. The UCC research team has successfully converted the STOPP/START rules to an electronic prototype which has very significant market potential as a tool for routine assessment of older people's medication, with a view to optimization of drug therapy and avoidance of preventable side-effects. Drug-related morbidity and mortality are recognized internationally as a highly significant public health problem; STOPP/START provides one possible method for addressing the growing problem of medication-related morbidity and mortality in older people. The total addressable market for the STOPP-START technology is estimated to be €300 million in Europe and up to €1 billion globally.
CSIS is taking this technology to market by collaborating with IT providers in the healthcare sector targeting primary care, pharmacies and hospitals in export markets in the UK, Europe, USA and other jurisdictions.

All Comments

Comments are disabled for this video.
When autoplay is enabled, a suggested video will automatically play next.

Up Next


Sign in to add this to Watch Later

Add to